Kalaris Therapeutics (KLRS) Change in Taxes (2022 - 2023)

Kalaris Therapeutics (KLRS) posted quarterly Change in Taxes of -$127000.0 for Q3 2023, down 4133.33% quarter-over-quarter from -$3000.0 in Q2 2023.

Kalaris Therapeutics (KLRS) Change in Taxes (2022 - 2023) Analysis & Trends

Kalaris Therapeutics' Change in Taxes history runs 2 years deep, the most recent figure standing at -$127000.0 for Q3 2023.

In Q3 2023, Change in Taxes changed N/A year-over-year to -$127000.0; the TTM figure through Dec 2023 stood at -$128000.0 (up 85.44% YoY), while the FY2023 annual figure was -$128000.0, up 85.44% from the prior year.
Change in Taxes for Q3 2023 stood at -$127000.0, down from -$3000.0 in the prior quarter.
The five-year high for Change in Taxes was $2000.0 in Q1 2023, with the low at -$500000.0 in Q1 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Taxes (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	90.33 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Kalaris Therapeutics	100.19 Mn	100.19 Mn	-	-

Download Data